Current Problems with Non-Specific COX Inhibitors
Journal:
Current Pharmaceutical Design
Volume:
6
Page:
1693-1724
Author(s):
Patricia McGettigan and David Henry
Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Journal:
Current Pharmaceutical Design
Volume:
6
Page:
1725-1736
Author(s):
Leslie J. Crofford
COX-2 and the Kidneys
Journal:
Current Pharmaceutical Design
Volume:
6
Page:
1737-1753
Author(s):
D. O. Stichtenoth and J. C. Frolich
Docosahexaenoic Acid and Membrane Lipid Domains
Journal:
Current Organic Chemistry
Volume:
4
Page:
1169-1183
Author(s):
William Stillwell
Biologic Agents in the Treatment of Rheumatoid Arthritis
Journal:
Current Pharmaceutical Biotechnology
Volume:
1
Page:
217-233
Author(s):
Boulos Haraoui, Vibeke Strand and Edward Keystone
Forecasting Roles of Combinatorial Chemistry in the Age of Genomically Derived Drug Discovery Targets
Journal:
Combinatorial Chemistry & High Throughput Screening
Volume:
3
Page:
421-436
Author(s):
David S. Thorpe
Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Journal:
Current Drug Metabolism
Volume:
1
Page:
193-204
Author(s):
B. Widner, M. Ledochowski and D. Fuchs
Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Journal:
Current Pharmaceutical Biotechnology
Volume:
1
Page:
11-31
Author(s):
W. Jelkmann
Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis
Journal:
Current Pharmaceutical Design
Volume:
6
Page:
943-959
Author(s):
Philip E. Morris,Jr. and George A. Omura
Consideration of Cytokines as Therapeutics Agents or Targets
Journal:
Current Pharmaceutical Design
Volume:
6
Page:
599-611
Author(s):
Zhou Xing and Jun Wang